175 related articles for article (PubMed ID: 35848061)
1. Tivozanib for the treatment of advanced renal cell carcinoma.
Chatzkel J; Ramnaraign B; Sonpavde G
Expert Opin Pharmacother; 2022 Jul; 23(10):1135-1142. PubMed ID: 35848061
[TBL] [Abstract][Full Text] [Related]
2. Tivozanib in relapsed or refractory advanced renal cell carcinoma: a focus on US approval.
Viray H; McDermott DF; Einstein DJ
Expert Rev Anticancer Ther; 2022 Jul; 22(7):695-702. PubMed ID: 35698870
[TBL] [Abstract][Full Text] [Related]
3. The role of tivozanib in advanced renal cell carcinoma therapy.
Escudier B; Porta C; Eisen T; Belsey J; Gibson D; Morgan J; Motzer R
Expert Rev Anticancer Ther; 2018 Nov; 18(11):1113-1124. PubMed ID: 30084668
[TBL] [Abstract][Full Text] [Related]
4. Long-Term Survival in Patients With Relapsed/Refractory Advanced Renal Cell Carcinoma Treated With Tivozanib: Analysis of the Phase III TIVO-3 Trial.
Beckermann KE; Asnis-Alibozek AG; Atkins MB; Escudier B; Hutson TE; Kasturi V; McDermott DF; Pal SK; Porta C; Rini BI; Verzoni E
Oncologist; 2024 Mar; 29(3):254-262. PubMed ID: 38262444
[TBL] [Abstract][Full Text] [Related]
5. Safety and Efficacy of Tivozanib in First-Line mRCC: A Multicenter Compassionate-Use Study (Meet-Uro 16).
Basso U; Procopio G; Fornarini G; Massari F; Bearz A; Fratino L; Milella M; Bassanelli M; Ermacora P; Bimbatti D; Verzoni E; Rizzo M; Porta C
Oncology; 2021; 99(12):747-755. PubMed ID: 34583356
[TBL] [Abstract][Full Text] [Related]
6. Tivozanib for the treatment of renal cell carcinoma.
Santoni M; Massari F; Piva F; Carrozza F; Di Nunno V; Cimadamore A; Martignetti A; Montironi R; Battelli N
Expert Opin Pharmacother; 2018 Jun; 19(9):1021-1025. PubMed ID: 29851529
[TBL] [Abstract][Full Text] [Related]
7. Profile of tivozanib and its potential for the treatment of advanced renal cell carcinoma.
Cowey CL
Drug Des Devel Ther; 2013; 7():519-27. PubMed ID: 23818763
[TBL] [Abstract][Full Text] [Related]
8. TiNivo: safety and efficacy of tivozanib-nivolumab combination therapy in patients with metastatic renal cell carcinoma.
Albiges L; Barthélémy P; Gross-Goupil M; Negrier S; Needle MN; Escudier B
Ann Oncol; 2021 Jan; 32(1):97-102. PubMed ID: 33010459
[TBL] [Abstract][Full Text] [Related]
9. Tivozanib, a highly potent and selective inhibitor of VEGF receptor tyrosine kinases, for the treatment of metastatic renal cell carcinoma.
Jacob A; Shook J; Hutson TE
Future Oncol; 2020 Oct; 16(28):2147-2164. PubMed ID: 32692256
[TBL] [Abstract][Full Text] [Related]
10. Tivozanib: practical implications for renal cell carcinoma and other solid tumors.
Berge EM; Bowles DW; Flaig TW; Lam ET; Jimeno A
Drugs Today (Barc); 2013 May; 49(5):303-15. PubMed ID: 23724410
[TBL] [Abstract][Full Text] [Related]
11. Antitumor activity and safety of tivozanib (AV-951) in a phase II randomized discontinuation trial in patients with renal cell carcinoma.
Nosov DA; Esteves B; Lipatov ON; Lyulko AA; Anischenko AA; Chacko RT; Doval DC; Strahs A; Slichenmyer WJ; Bhargava P
J Clin Oncol; 2012 May; 30(14):1678-85. PubMed ID: 22493422
[TBL] [Abstract][Full Text] [Related]
12. Activity of Tivozanib in Non-clear Cell Renal Cell Carcinoma: Subgroup Analysis From a Phase II Randomized Discontinuation Trial.
Barata PC; Chehrazi-Raffle A; Allman KD; Asnis-Alibozek A; Kasturi V; Pal SK
Oncologist; 2023 Oct; 28(10):894-900. PubMed ID: 37315114
[TBL] [Abstract][Full Text] [Related]
13. Tivozanib: A New Hope for Treating Renal Cell Carcinoma.
Passi I; Billowria K; Kumar B; Chawla PA
Anticancer Agents Med Chem; 2023; 23(5):562-570. PubMed ID: 35718972
[TBL] [Abstract][Full Text] [Related]
14. Tivozanib: a new treatment option for renal cell carcinoma.
Saes L; Eskens FALM
Drugs Today (Barc); 2017 Nov; 53(11):609-618. PubMed ID: 29451277
[TBL] [Abstract][Full Text] [Related]
15. Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study.
Rini BI; Pal SK; Escudier BJ; Atkins MB; Hutson TE; Porta C; Verzoni E; Needle MN; McDermott DF
Lancet Oncol; 2020 Jan; 21(1):95-104. PubMed ID: 31810797
[TBL] [Abstract][Full Text] [Related]
16. Tivozanib for the treatment of renal cell carcinoma: results and implications of the TIVO-1 trial.
Mehta A; Sonpavde G; Escudier B
Future Oncol; 2014 Aug; 10(11):1819-26. PubMed ID: 25325825
[TBL] [Abstract][Full Text] [Related]
17. Progress and contrasts of the development of tivozanib for therapy of kidney cancer.
Gupta S; Fishman M
Expert Opin Pharmacother; 2011 Dec; 12(18):2915-22. PubMed ID: 22098229
[TBL] [Abstract][Full Text] [Related]
18. Tivozanib: First Global Approval.
Kim ES
Drugs; 2017 Nov; 77(17):1917-1923. PubMed ID: 28971328
[TBL] [Abstract][Full Text] [Related]
19. FDA Approval Summary: Tivozanib for Relapsed or Refractory Renal Cell Carcinoma.
Chang E; Weinstock C; Zhang L; Fiero MH; Zhao M; Zahalka E; Ricks TK; Fourie Zirkelbach J; Qiu J; Yu J; Chen XH; Bhatnagar V; Goldberg KB; Tang S; Kluetz PG; Pazdur R; Ibrahim A; Beaver JA; Amiri-Kordestani L
Clin Cancer Res; 2022 Feb; 28(3):441-445. PubMed ID: 34417198
[TBL] [Abstract][Full Text] [Related]
20. Tivozanib for the treatment of metastatic renal cancer.
Wong HH; Eisen T
Expert Rev Anticancer Ther; 2013 Jun; 13(6):649-60. PubMed ID: 23773100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
